NCT07291232

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Multiple Subcutaneous Doses of ABBV-295 in Adult Subjects With Obesity

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 96 (estimated)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	ABBV-295	Subcutaneous Injections
DRUG	Placebo	Subcutaneous Injections

Timeline

• Start date: 2025-11-19
• Primary completion: 2026-10-01
• Completion: 2026-10-01
• First posted: 2025-12-18
• Last updated: 2025-12-18

Locations

1 site across 1 country: United States